Throughout early discovery and particularly for market release, biologic drug candidates require mechanism-of-action (MOA)-based functional, cellular assays as characterisation tools that can attest to their desired therapeutic activity. However, developing such physiologically relevant cell-based assays has proved to be challenging and they are often difficult to establish in quality control (QC) labs, with long and complicated assay protocols or using primary cells. In this webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
